168 related articles for article (PubMed ID: 29687002)
1. Identification of Key Candidate Proteins and Pathways Associated with Temozolomide Resistance in Glioblastoma Based on Subcellular Proteomics and Bioinformatical Analysis.
Yi GZ; Xiang W; Feng WY; Chen ZY; Li YM; Deng SZ; Guo ML; Zhao L; Sun XG; He MY; Qi ST; Liu YW
Biomed Res Int; 2018; 2018():5238760. PubMed ID: 29687002
[TBL] [Abstract][Full Text] [Related]
2. The E3 Ubiquitin Ligase NEDD4-1 Mediates Temozolomide-Resistant Glioblastoma through PTEN Attenuation and Redox Imbalance in Nrf2-HO-1 Axis.
Chuang HY; Hsu LY; Pan CM; Pikatan NW; Yadav VK; Fong IH; Chen CH; Yeh CT; Chiu SC
Int J Mol Sci; 2021 Sep; 22(19):. PubMed ID: 34638586
[TBL] [Abstract][Full Text] [Related]
3. Sulforaphane reverses chemo-resistance to temozolomide in glioblastoma cells by NF-κB-dependent pathway downregulating MGMT expression.
Lan F; Yang Y; Han J; Wu Q; Yu H; Yue X
Int J Oncol; 2016 Feb; 48(2):559-68. PubMed ID: 26648123
[TBL] [Abstract][Full Text] [Related]
4. Sulforaphane enhances temozolomide-induced apoptosis because of down-regulation of miR-21 via Wnt/β-catenin signaling in glioblastoma.
Lan F; Pan Q; Yu H; Yue X
J Neurochem; 2015 Sep; 134(5):811-8. PubMed ID: 25991372
[TBL] [Abstract][Full Text] [Related]
5. Targeting miR-381-NEFL axis sensitizes glioblastoma cells to temozolomide by regulating stemness factors and multidrug resistance factors.
Wang Z; Yang J; Xu G; Wang W; Liu C; Yang H; Yu Z; Lei Q; Xiao L; Xiong J; Zeng L; Xiang J; Ma J; Li G; Wu M
Oncotarget; 2015 Feb; 6(5):3147-64. PubMed ID: 25605243
[TBL] [Abstract][Full Text] [Related]
6. Long-term in vitro treatment of human glioblastoma cells with temozolomide increases resistance in vivo through up-regulation of GLUT transporter and aldo-keto reductase enzyme AKR1C expression.
Le Calvé B; Rynkowski M; Le Mercier M; Bruyère C; Lonez C; Gras T; Haibe-Kains B; Bontempi G; Decaestecker C; Ruysschaert JM; Kiss R; Lefranc F
Neoplasia; 2010 Sep; 12(9):727-39. PubMed ID: 20824049
[TBL] [Abstract][Full Text] [Related]
7. YKL-40 downregulation is a key factor to overcome temozolomide resistance in a glioblastoma cell line.
Akiyama Y; Ashizawa T; Komiyama M; Miyata H; Oshita C; Omiya M; Iizuka A; Kume A; Sugino T; Hayashi N; Mitsuya K; Nakasu Y; Yamaguchi K
Oncol Rep; 2014 Jul; 32(1):159-66. PubMed ID: 24842123
[TBL] [Abstract][Full Text] [Related]
8. Up-regulation of MSH6 is associated with temozolomide resistance in human glioblastoma.
Sun Q; Pei C; Li Q; Dong T; Dong Y; Xing W; Zhou P; Gong Y; Zhen Z; Gao Y; Xiao Y; Su J; Ren H
Biochem Biophys Res Commun; 2018 Feb; 496(4):1040-1046. PubMed ID: 29366782
[TBL] [Abstract][Full Text] [Related]
9. Up-Regulation of Cyclooxygenase-2 (COX-2) Expression by Temozolomide (TMZ) in Human Glioblastoma (GBM) Cell Lines.
Lombardi F; Augello FR; Artone S; Gugu MK; Cifone MG; Cinque B; Palumbo P
Int J Mol Sci; 2022 Jan; 23(3):. PubMed ID: 35163465
[TBL] [Abstract][Full Text] [Related]
10. FoxO3a induces temozolomide resistance in glioblastoma cells via the regulation of β-catenin nuclear accumulation.
Xu K; Zhang Z; Pei H; Wang H; Li L; Xia Q
Oncol Rep; 2017 Apr; 37(4):2391-2397. PubMed ID: 28260024
[TBL] [Abstract][Full Text] [Related]
11. Temozolomide resistance in glioblastoma occurs by miRNA-9-targeted PTCH1, independent of sonic hedgehog level.
Munoz JL; Rodriguez-Cruz V; Ramkissoon SH; Ligon KL; Greco SJ; Rameshwar P
Oncotarget; 2015 Jan; 6(2):1190-201. PubMed ID: 25595896
[TBL] [Abstract][Full Text] [Related]
12. Nuclear factor I A promotes temozolomide resistance in glioblastoma via activation of nuclear factor κB pathway.
Yu X; Wang M; Zuo J; Wahafu A; Mao P; Li R; Wu W; Xie W; Wang J
Life Sci; 2019 Nov; 236():116917. PubMed ID: 31614149
[TBL] [Abstract][Full Text] [Related]
13. Temozolomide treatment combined with AZD3463 shows synergistic effect in glioblastoma cells.
Goker Bagca B; Ozates NP; Asik A; Caglar HO; Gunduz C; Biray Avci C
Biochem Biophys Res Commun; 2020 Dec; 533(4):1497-1504. PubMed ID: 33109342
[TBL] [Abstract][Full Text] [Related]
14. miR-1268a regulates ABCC1 expression to mediate temozolomide resistance in glioblastoma.
Li Y; Liu Y; Ren J; Deng S; Yi G; Guo M; Shu S; Zhao L; Peng Y; Qi S
J Neurooncol; 2018 Jul; 138(3):499-508. PubMed ID: 29876787
[TBL] [Abstract][Full Text] [Related]
15. MALAT1 is a prognostic factor in glioblastoma multiforme and induces chemoresistance to temozolomide through suppressing miR-203 and promoting thymidylate synthase expression.
Chen W; Xu XK; Li JL; Kong KK; Li H; Chen C; He J; Wang F; Li P; Ge XS; Li FC
Oncotarget; 2017 Apr; 8(14):22783-22799. PubMed ID: 28187000
[TBL] [Abstract][Full Text] [Related]
16. Long Non-Coding RNA MALAT1 Decreases the Sensitivity of Resistant Glioblastoma Cell Lines to Temozolomide.
Li H; Yuan X; Yan D; Li D; Guan F; Dong Y; Wang H; Liu X; Yang B
Cell Physiol Biochem; 2017; 42(3):1192-1201. PubMed ID: 28668966
[TBL] [Abstract][Full Text] [Related]
17. Metformin treatment reduces temozolomide resistance of glioblastoma cells.
Yang SH; Li S; Lu G; Xue H; Kim DH; Zhu JJ; Liu Y
Oncotarget; 2016 Nov; 7(48):78787-78803. PubMed ID: 27791206
[TBL] [Abstract][Full Text] [Related]
18. EFEMP1 induces γ-secretase/Notch-mediated temozolomide resistance in glioblastoma.
Hiddingh L; Tannous BA; Teng J; Tops B; Jeuken J; Hulleman E; Boots-Sprenger SH; Vandertop WP; Noske DP; Kaspers GJ; Wesseling P; Wurdinger T
Oncotarget; 2014 Jan; 5(2):363-74. PubMed ID: 24495907
[TBL] [Abstract][Full Text] [Related]
19. Identification of potential glioma drug resistance target proteins based on ultra-performance liquid chromatography-mass spectrometry differential proteomics.
Li D; Yan J; Li K; Yang Q; Bian L; Lin B; Liu X; Xi Z
PeerJ; 2023; 11():e16426. PubMed ID: 38054015
[TBL] [Abstract][Full Text] [Related]
20. The histone demethylase KDM5A is a key factor for the resistance to temozolomide in glioblastoma.
Banelli B; Carra E; Barbieri F; Würth R; Parodi F; Pattarozzi A; Carosio R; Forlani A; Allemanni G; Marubbi D; Florio T; Daga A; Romani M
Cell Cycle; 2015; 14(21):3418-29. PubMed ID: 26566863
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
